D-Ala-D-Ala peptidoglycan precursors — Drug Target

2 drugs 1 marketed 1 in Phase 3

All drugs that target D-Ala-D-Ala peptidoglycan precursors — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Lipoglycopeptide antibiotic

Marketed (1)

Dalbavancin via Intravenous Administration · University of Colorado, Denver · Lipoglycopeptide antibiotic · Infectious Disease
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.

Phase 3 pipeline (1)

IV Dalbavancin · Durata Therapeutics Inc., an affiliate of Allergan plc · Lipoglycopeptide antibiotic · Infectious Disease
Dalbavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors.